Drugs Made In America Acquisition DMAA
NASDAQ DMAA
$10.74 +0.01 (+0.14%)
As of: Aug 21, 2026 · 2:31 PM EDT

Drugs Made In America Acquisition (DMAA) Non-Current Debt (2024 - 2025)

Drugs Made In America Acquisition's (DMAA) quarterly Non-Current Debt came in at $60898.0 in Q1 2025, down 90.81% on a QoQ basis from $662324.0 in Q4 2024.

Drugs Made In America Acquisition (DMAA) Non-Current Debt (2024 - 2025) Analysis & Trends

Drugs Made In America Acquisition (DMAA) has 2 years of Non-Current Debt data on file, last reported at $60898.0 in Q1 2025.

  • Quarterly Non-Current Debt changed N/A year-over-year to $60898.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $60898.0 (changed N/A YoY) and the FY2024 annual result came in at $662324.0, changed N/A from the prior year.
  • Non-Current Debt declined to $60898.0 in Q1 2025, from $662324.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $662324.0 in Q4 2024 to a low of $60898.0 in Q1 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Oxley Bridge Acquisition 585.76 Mn 585.76 Mn - -
2 Launch Two Acquisition 557.86 Mn 557.86 Mn - -
3 Drugs Made In America Acquisition 507.00 Mn 507.00 Mn - -
4 Cantor Equity Partners IV 468.00 Mn 468.00 Mn - -
5 GP-Act III Acquisition 401.06 Mn 401.06 Mn - -
6 Aldel Financial 397.49 Mn 397.49 Mn - -
7 Republic Digital Acquisition 389.25 Mn 388.51 Mn - -
8 Gores Holdings X 385.06 Mn 384.87 Mn - -
9 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn - 5.27 Mn
10 Drugs Made In America Acquisition 215.82 Mn 215.82 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2025 60,898.00
Dec 31, 2024 662,324.00